The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 7, 2004, Pages 2624-2632

  Dow, Geoffrey S ^a   Koenig, Michael L ^a   Wolf, Lesley ^a   Gerena, Lucia ^a   Lopez Sanchez, Miriam ^a   Hudson, Thomas H ^a   Bhattacharjee, Apurba K ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 QUINOLINECARBINOLAMINE DERIVATIVE; 6,8 DICHLORO ALPHA (2 PIPERIDYL) 2 TRIFLUOROMETHYL 4 QUINOLINEMETHANOL; AMODIAQUINE; ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; HALOFANTRINE; HYDROXYCHLOROQUINE SULFATE; HYPOXANTHINE; MEFLOQUINE; QUININE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WR 006006; WR 007333; WR 007552; WR 007573; WR 007930; WR 007936; WR 062175; WR 073872; WR 073879; WR 073892; WR 073898; WR 122950; WR 157801; WR 159314; WR 187044; WR 228974;

ACCURACY; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMALARIAL ACTIVITY; ARTICLE; CELL ASSAY; CENTRAL NERVOUS SYSTEM DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DIZZINESS; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; HALLUCINATION; HEADACHE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; INSOMNIA; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PHARMACOPHORE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SEIZURE; STRUCTURE ANALYSIS; TECHNIQUE; TOXICITY TESTING; VIVID DREAM;

ANIMALS; ANTIMALARIALS; CALCIUM; CELLS, CULTURED; DRUG RESISTANCE; HOMEOSTASIS; MEFLOQUINE; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; NERVOUS SYSTEM DISEASES; NEURONS; PHENANTHRENES; PLASMODIUM FALCIPARUM; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS;

EID: 3042616941     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.7.2624-2632.2004     Document Type: Article

References (30)

1. Accelrys Inc. 2001. CATALYST, version 4.6. Accelrys Inc., San Diego, Calif.
2. Baudry, S., Y. T. Pham, B. Baune, S. Vidrequin, C. Crevoisier, F. Gimenez, and R. Farinotti. 1997. Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J. Pharm. Pharmacol. 49:1086-1090.
3. Bhattacharjee, A. K., and J. M. Karle. 1996. Molecular electronic properties of a series of 4-quinolinecarbinolamines define antimalarial activity profile. J. Med. Chem. 39:4622-4629.
4. Bhattacharjee, A. K., D. E. Kyle, J. L. Vennerstrom, and W. K. Milhous. 2002. A 3D QSAR pharmacophore model and quantum chemical structure activity analysis of chloroquine (CQ)-resistance reversal. J. Chem. Inf. Comput. Sci, 42:1212-1220.
5. Canfield, C. J. 1980. Antimalarial aminoalcohol alternatives to mefloquine. Acta Trop. 37:232-237.
6. Choi, D. W. 1988. Calcium-mediated neurotoxicity: relationship to specific channel types and roles in ischemic damage, Trends Neurosci. 11:465-469.
7. Cook, G. C. 1995. Mefloquine prophylaxis. Mefloquine toxicity should limit its use to treatment alone. BMJ 311:190-191.
8. Croft, A. M., and P. Garner. 2000, Mefloquine for preventing malaria in non-immune adult travelers. Cochrane Database Syst. Rev. 3:CD000138.
9. Desjardins, R. E., C. J. Canfield, J. D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
10. Dow, G. S., T. H. Hudson, M. Vahey, and M. L. Koenig. 2003. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro, Malaria J. 2:14.
11. Foley, M., and L. Tilley. 1998. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79:55-87.
12. Grigorov, M., J. Weber, J. M. Tronchet, C. W. Jefford, W. K. Milhous, and D. Maric. 1997, A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes, J. Chem. Inf. Comput. Sci. 37:124-130.
13. Hartley, D. M., M. C. Kurth, L. Bjerkness, J. H. Weiss, and D. W. Choi. 1993. Glutamate receptor-induced 45Ca2+ accumulation in cortical cell cultures correlates with subsequent neuronal degeneration. J. Neurosci. 13:1993-2000.
14. Jones, R., G. Kunsman, B. Levine, M. Smith, and C. Stahl. 1994. Mefloquine distribution in postmortem cases. Forensic Sci. Int. 68:29-32.
15. Koenig, M. L., C. M. Sgarlat, D. L. Yourick, J. B. Long, and J. L. Meyerhoff. 2001. In vitro neuroprotection against glutamate-induced toxicity by pGlu-Glu-Pro-NH(2) (EEP). Peptides 22:2091-2097.
16. Kollaritsch, H., J. Karbwang, G. Weidermann, A. Mikolasek, K. Na-Bangchang, and W. H. Wernsdorfer. 2000. Mefloquine concentration profiles during prophylactic dose regimens. Wein. Klin. Wochenschr. 112:441-447.
17. Milhous, W. K., N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1985. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob. Agents Chemother. 27:525-530.
18. National Center for Infectious Diseases. 2003. Accession date,z 19 February 2004. Prescription drugs for preventing malaria. [Online.] Centers for Disease Control and Prevention. http://www.cdc.gov/travel/malariadrugs.htm.
19. Oduola, A. M., W. K. Milhous, N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1988. Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp. Parasitol. 67:354-360.
20. Overbosch, D., H. Schilthuis, U. Bienzle, R. H. Behrens, K. C. Kain, P. D. Clarke, S. Toovey, J. Knobloch, H. D. Nothdurft, D. Shaw, N. S. Roskell, and J. D. Chulay. 2001. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. Clin. Infect. Dis. 33:1015-1021.
21. Pham, Y. T., F. Nosten, R. Farinotti, N. J. White, and F. Gimenez. 1999. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int. J. Clin. Pharmacol, Ther. 37:58-61.
22. Phillips-Howard, P. A., and F. O. ter Kuile. 1995. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf. a370-383.
23. Schlagenhauf, P. 1999. Mefloquine for malaria chemoprophylaxis 1992-1998. J. Travel Med. 6:122-133.
24. Shepherd, J. September 1998. Use of (+) mefloquine for the treatment of malaria. International patent WO98/39003.
25. Simpson, J., A. Price, R. ter Kuile, F. Teja-Isavatharm, P. Nosten, F. Chongsuphajaisiddhi, T. Looareesuwan, S. L. Aarons, and N. J. White. 1999. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 66:472-484.
26. Speich, R., and A. Haller. 1994, Central anticholinergic syndrome with the antimalarial drug mefloquine, N. Engl. J. Med. 331:57-58.
27. Stocks, P. A., K. J. Raynes, and S. A. Ward. 2001. Novel quinoline antimalarials, p 235-253. In P. Rosenthal (ed.). Antimalarial chemotherapy: mechanism of action, resistance and new directions in drug discovery. Humana Press Inc., Totowa, N.J.
28. Sutter, J., O. Guner, R. Hoffman, H. Li, and M. Waldman. 2000. Effect of variable weights and tolerances on predictive model generation, p. 501-511. In O. F. Guner (ed.), Pharmacophore, perception, development, and use in drug design, International University Line, La Jolla, Calif.
29. Sweeney, T. R. 1991. A survey of compounds from the antimalarial drug development program of the U.S. Army Medical Research and Development Command, vol. 1. Walter Reed Army Institute of Research, Washington, D.C.
30. World Health Organization. 1998. The World Health Report 1998. World Health Organization, Geneva, Switzerland.